Browse > Article
http://dx.doi.org/10.4333/KPS.2009.39.3.173

New Crystal form of Valsartan Dipotassium Salt  

Seo, Sung-Ki (R&D Center, Kuhnil Pharm. Co., Ltd.)
Kim, Dae-Duk (Department of Pharmaceutics, College of Pharmacy, Seoul National University)
Oh, Eui-Chaul (R&D Center, Kuhnil Pharm. Co., Ltd.)
Publication Information
Journal of Pharmaceutical Investigation / v.39, no.3, 2009 , pp. 173-176 More about this Journal
Abstract
A new crystal form of valsartan dipotassium was isolated by recrystallization using the one-pot method. The new crystal form was identified as a monohydrate form ($C_{24}H_{27}N_5O_3K_2.H_2O$) and characterized by diffential scanning calorimetry (DSC), thermogravimetric analysis (TGA) and X-ray powder diffractometry (PXRD). The new crystal data demonstrated to be clearly different from those known for the tetrahydrate form ($C_{24}H_{27}N_5O_3K_2.4H_2O$). It was observed that the monohydrate of vasartan dipotassium salt was completely dissolved in water within 1 hour and its dissolution rate was much faster than anhydrous free form of valsartan.
Keywords
Valsartan; Dipotassium Salt; Crystal Form; Hydrate; DSC; TGA; PXRD;
Citations & Related Records
연도 인용수 순위
  • Reference
1 E.S. Jones, A. Vinh, C.A. McCarthy, T.A. Gaspari and R.E. Widdop, AT2 receptors: Functional relevance in cardiovascular disease, Pharmacology & Therapeutics, 120, 292-316 (2008)   DOI   ScienceOn
2 K. Kamada, S. Yoshimura, M. Murata, H. Murata, H. Nagai, H. Ushio and K. Terada, Characterization and monitoring of pseudo-polymorphs in manufacturing process by NIR, International Journal of Pharmaceutics, 368, 103-108 (2009)   DOI   ScienceOn
3 Y.T. Shon, Pharmaceutical application of polymorphism, Pharmacon, 21, 500-516(1981).
4 V.M. Rao, R. Sanghvi and H. Zhu, Solubility of Pharmaceutical Solids, Developing Solid Oral Dosage Forms, 1-24 pages (2009)
5 E.F. Fies and T.A. Hagen, Preformulation. In Theory and Practice of Industrial Pharmacy. Edited by L. Lachman, H. A. Lieberman and J. L. Kanig, Third Edition, Lea and Febiger, 1986 Philadelphia, pp. 171
6 N. Kaneniwa, M. Otsuka, T. Yamaguchi, T. Hayashi, K. Hayashi, T. Matsumoto, N. Watari and O. Unezawa, Preparation of polymorphs of some crystalline drug powders, Funsai, 33, 30-40 (1989)
7 C. Lu, Y. Chang, W. Tseng, C. Feng and C. Lu, Analysis of angiotensin II receptor antagonist and protein markers at microliter level plasma by LC-MS/MS, Journal of Pharmaceutical and Biomedical Analysis, 49, 123-128 (2009)   DOI   ScienceOn
8 V.A. Ostrovskii, G.I. Koldobskii and R.E. Trifonov, Tetrazoles, Comprehensive Heterocyclic Chemistry III, 257-423 (2008)
9 F.W. Langkilde, J. Sjoblom, L. Tekenbergs-Hjelte and J. Mrak, Quantitative FT-Raman analysis of two crystal forms of a pharmaceutical compound, Journal of Pharmaceutical and Biomedical Analysis, 15, 687-696 (1997)   DOI   ScienceOn
10 F. Bayard, C. Decoret and J. Royer, Structural aspects of polymorphism and phase transition in organic molecular crystals, Stud. Phys. Threo. Chem. 69, 211-234 (1990)
11 L.M. Katrincic, Y. T. Sun, R. A. Carlton, A. M. Diederich, R. L. Mueller and F. G. Vogt, Characterization, selection, and development of an orally dosed drug polymorph from an enantiotropically related system, International Journal of Pharmaceutics, 366, 1-13 (2009)   DOI   ScienceOn